Novo Nordisk is to pay $200m upfront to in-license a ‘triple G’ agonist obesity candidate, helping it compete head-to-head with fierce rival Eli Lilly.
Novo Gets Its Own ‘Triple G’ Obesity Drug To Rival Lilly
The obesity market leader is teaming up with China’s United Bio-Technology to develop a product they believe could beat Lilly’s late-stage same-class candidate retatrutide.
